Adverum Biotechnologies Inc

Adverum Biotechnologies — Investor Presentation (October 2016)

15 slides from Adverum Biotechnologies's investor presentation, Oct 13, 2016

  1. Slide 1: Gaining Momentum in Gene Therapy

    Slide 1: Gaining Momentum in Gene Therapy

    Gaining Momentum in Gene Therapy Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained in this document regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Adverum

  3. Slide 3: Adverum is uniquely positioned to deliver gene therapy treatments to patients successfully

    Slide 3: Adverum is uniquely positioned to deliver gene therapy treatments to patients successfully

    Adverum is uniquely positioned to deliver gene therapy treatments to patients successfully Supply Chain Manufacturing platform applicable across pipeline Fully scalable upstream and downstream processes GMP Quality Control Pipeline Clear unmet need Defined patient population Validated targets Define

  4. Slide 4: Lead and Partnered Programs

    Slide 4: Lead and Partnered Programs

    Product Candidate Indication Stage of Development Research Preclinical Phase 1/2 Lead Program Pipeline ADVM-022/032 (Ocular Disease) Wet AMD ANN-001 (Rare Disease) A1AT Deficiency ANN-002 (Rare Disease) Hereditary Angioedema Partnered Program Pipeline AVA-311 (Ocular Disease) XLRS 3 Undisclosed Targ

  5. Slide 5: Lead Programs: ADVM-022 and ADVM-032 for wAMD, ANN-002 for HAE, ANN-001 for A1AT

    Slide 5: Lead Programs: ADVM-022 and ADVM-032 for wAMD, ANN-002 for HAE, ANN-001 for A1AT

    Lead Programs ADVM-022 and ADVM-032 for wet Age-Related Macular Degeneration (wAMD) III. ANN-002 for Hereditary Angioedema (HAE) II. ANN-001 for Alpha-1 Antitrypsin Deficiency (A1AT)

  6. Slide 6: wAMD – Summary

    Slide 6: wAMD – Summary

    wAMD – Summary 1Arch Ophthalmol. 2004;122(4):564-572. doi:10.1001/archopht.122.4.564 Disease Description Leading cause of visual deterioration and legal blindness in patients over 60 years of age New abnormal blood vessels form in the eye which leak and bleed into the macula (choroidal neovasculariz

  7. Slide 7: De facto under-treatment leads to suboptimal visual outcomes for patients

    Slide 7: De facto under-treatment leads to suboptimal visual outcomes for patients

    De facto under-treatment leads to suboptimal visual outcomes for patients Average Injections Per Year (Lucentis + Avastin, Medicare Data) Recommended Dosing 12 Number of injections per year Real world data indicate de facto “under-treatment” 1 Holekamp NM, et al. Am J Ophthalmol. 2014;157(4):825-833

  8. Slide 8: Laser Induced CNV Model in Nonhuman Primates Used to Assess ADVM-022 and ADVM-032

    Slide 8: Laser Induced CNV Model in Nonhuman Primates Used to Assess ADVM-022 and ADVM-032

    Laser Induced Choroidal Neovascularization (CNV) Model in Nonhuman Primates Used to Assess ADVM-022 and ADVM-032 Laser treatments performed two months following administration of gene therapy or vehicle (negative control) Positive control animals received standard of care anti-VEGF proteins at time

  9. Slide 9: Single Intravitreal Injection of ADVM-022 or ADVM-032 Demonstrated Comparable Efficacy to Standard of Care

    Slide 9: Single Intravitreal Injection of ADVM-022 or ADVM-032 Demonstrated Comparable Efficacy to Standard of Care

    A Single Intravitreal Injection of ADVM-022 or ADVM-032 Demonstrated Comparable Efficacy to Standard of Care Intravitreal anti-VEGF Protein in Laser CNV Model ADVM-022 ADVM-032 * p < 0.0001 vs vehicle * p < 0.0001 vs vehicle

  10. Slide 10: ADVM-022 and -032 in wAMD: Key Attributes and Next Steps

    Slide 10: ADVM-022 and -032 in wAMD: Key Attributes and Next Steps

    ADVM-022 and -032 in wAMD: Key Attributes and Next Steps Novel vector Novel capsid Delivered intravitreally Less invasive More robust delivery across patients Preclinical studies suggest the potential to: Minimize the treatment burden of frequent injections Maximize clinical outcomes Key Attributes

  11. Slide 11: Focus on Manufacturing to Ensure Product Supply Throughout Product Development Life Cycle

    Slide 11: Focus on Manufacturing to Ensure Product Supply Throughout Product Development Life Cycle

    Focus on Manufacturing to Ensure Product Supply Throughout Product Development Life Cycle and Beyond In house process development capabilities to deliver turn-key large scale process to CMO Scalable upstream process using the baculovirus/SF9 system of expression for AAV production State-of-the-art b

  12. Slide 12: Strong Emphasis on Discovery of Novel Vectors and Expression Cassettes

    Slide 12: Strong Emphasis on Discovery of Novel Vectors and Expression Cassettes

    Strong Emphasis on Discovery of Novel Vectors and Expression Cassettes to Improve on Existing Technology Next generation vectors through Directed Evolution and Rational Design of AAV capsids for better transduction efficiency and antibody neutralization profiles Discovery of improved ubiquitous and

  13. Slide 13: Collaborations Leverage Our Leadership in Ophthalmic Vector Development

    Slide 13: Collaborations Leverage Our Leadership in Ophthalmic Vector Development

    Collaborations Leverage Our Leadership in Ophthalmic Vector Development Up to eight distinct therapeutic targets AVA-311 for juvenile X-Linked Retinoschisis (XLRS) is first collaboration program 3 other targets chosen but remain undisclosed Adverum option to share up to 35% on profits and developmen

  14. Slide 14: Adverum Financial Information

    Slide 14: Adverum Financial Information

    Adverum Financial Information Total Shares Outstanding (as of 9/23/16) 41.5 M Existing cash expected to be sufficient to fund lead programs through meaningful human proof-of-concept Pro Forma TSO including Options, RSU’s and Warrants (TSM as of 9/23/16) Cash at June 30, 2016 $241 M 43.7 M

  15. Slide 15: Adverum Biotechnologies

    Slide 15: Adverum Biotechnologies

    RKOVERUM BIOTECHNOLOGIES

Source: SEC EDGAR · 8-K filed Oct 13, 2016

More decks from Adverum Biotechnologies Inc